•  09:00 - 13:00 
     Workshop 1/4 
     Canada, Malta, 
     United Kingdom, Germany 

    preet marwaha cannabis summit world speaker

    Preet
    Marwaha

  •  09:00 - 13:00 
     Conference 1/4 
     Regulation, Legislation 
     & The Role of Big Pharma 

  • 09:00 - 09:20 | Conference Inauguration - Welcome Remarks

  • 09:20 - 09:30 | Malta's Journey

    What key drivers were behind the introduction of the production of cannabis for medicinal use act?

    miriam dalli cannabiz summit world speaker

    Miriam
    Dalli

  • 09:30 - 09:40 | Research and Development

    How has the change in law affected the scientific sector in Malta?

    deo debattista cannabis summit world speaker

    Deo
    Debattista

  • 09:40 - 10:00 | The Future of Medical Cannabis

    How will a patient-centric approach affect policy and supply chain decisions?

  • 10:00 - 10:10 | Managing Fibromyalgia

    What does the latest research say about managing symptoms of fibromyalgia with cannabis?

  • 10:10 - 10:20 | Chronic Pain Management

    What is the appropriate use of medical cannabis for patients with chronic pain?

    silviu brill cannabis summit world speaker

    Silviu
    Brill

  • 10:20 - 10:30 | Cancer Treatment

    Review of the latest research on the use of medical cannabis for the treatment of cancer.

  • 10:30 - 10:40 | Alternative Options

    The argument for boosting the body's natural endocannabinoids.

    giuseppe di giovanni cannabis summit world speaker

    Giuseppe
    Di Giovanni

  • 10:40 - 11:00 | WHO and its Impact on National Policies

    International organisations such as the World Health Organisation are becoming increasingly vocal on the application of medical cannabis. How is this impacting policy makers at state-level across different continents?

    monty munford cannabiz summit world speaker

    Monty
    Munford

  • 11:00 - 11:10 | Monitoring and Control

    What steps are being taken towards standardisation and quality control on a European level?

  • 11:10 - 11:20 | From Cultivation to Waste Disposal

    How is Malta enforcing regulatory procedures?

  • 11:20 - 11:30 | Intellectual Property and its Challenges

    How can pharmaceutical companies develop an effective intellectual property and commercial strategy for synthetic cannabinoids?

    Gabriel
    Micallef

  • 11:30 - 11:50 | Synthetic Cannabinoids

    what are the benefits and disadvantages of man-made cannabinoids?

    Manit
    Patel

  • 11:50 - 12:00 | Broad Uses of Medical Cannabis

    How is the legalisation of botanical-derived medical cannabis and its reputation as a treatment for multiple illnesses affecting the sale of other drugs by pharmaceutical companies?

  • 12:00 - 12:10 | Investment and Big Pharma

    There's no doubt pharmaceutical companies have the resources to research, develop and market synthetic cannabinoids. With demand exceeding supply in the market how might they use this to carve out their niche in the industry?

  • 12:10 - 12:20 | A Long Process

    Pharmaceutical companies have a notoriously long process to get a drug approved. If they move in the direction of synthetic cannabinoids how can they avoid losing out due to the long and expensive timeline?

  • 12:20 - 12:30 | Social Trends

    Medical cannabis is being championed as a natural remedy which can treat a variety of physical and psychological disorders. How might this social shift towards herbal based drugs stack up against the reputation of pharmaceutical companies?

  • 12:30 - 14:00 | Start-up Pitch

    10 medical cannabis startups with the most innovative projects will pitch on stage in front of established entrepreneurs and savvy investors . Set your sights on the moon and battle it out in a shark-tank environment with some tough love from a select panel of stern judges.

  •  14:00 - 18:00 
     Workshop 2/4 
     Australia, New Zealand, 
     Asia, LatAm, United States 

  •  14:00 - 18:00 
     Conference 2/4 
     Investment Opportunities 
     & The Start-Up Pitch 

  • 14:00 - 14:10 | Case Study

    From concept to exit, review of a successful start-up investment.

  • 14:10 - 14:30 | Mergers & Acquisitions

    As Big Tobacco and Big Alcohol get involved in the medical cannabis industry, how will this affect global markets?

  • 14:30 - 14:40 | Pick and Shovel Play

    How are investors using this strategy to mitigate risk in volatile cannabis stocks?

  • 14:40 - 14:50 | ETFs

    What's the advantages of entering the medical cannabis investment market via exchange traded funds?

  • 14:50 - 15:00 | Review

    Which are the best medical cannabis stocks and what can future big players learn from them?

  • 15:00 - 15:10 | Economic Sectors

    In which other ways does the production of medical cannabis benefit a country's other economic sectors?

  • 15:10 - 15:30 | Fund Restrictions

    Depending on the type of funds they have access to, some investors cannot put capital into the cultivation of the crop, only technology and services that are not related to the plant itself. How is this restricting start-ups from getting the capital they need?

  • 15:30 - 15:40 | Mergers & Acquisitions

    This is already a feature of the medical cannabis sector. How might it affect its future in Europe?

  • 15:40 - 15:50 | Emerging Markets

    How does medical cannabis compare to other emerging markets?

  • 15:50 - 16:00 | Ancilliary Services

    What sort of investment is required in ancillary services in order to support the medical cannabis sector?

  • 16:00 - 16:20 | From ICO's to Cannabis

    Following the recent pitfall that many investors have experienced with ICO's worldwide, could cannabis pave the way for more secure investment opportunities?

  • 16:20 - 16:30 | Market Overview

    What is the European medicinal cannabis market worth and what are the future projections?

  • 16:30 - 16:40 | Funding and Research

    Both the public and private sector are investing in scientific research. How can the two work together for both the benefit of patients and future commercial success?

  • 16:40 - 16:50 | Mitigating Risk

    Investment firms have highlighted several risk factors in investing in the European medical cannabis industry. How are these to be reduced?

  • 16:50 - 17:10 | VC's and PE

    Venture capitalists and private equity funds are heavily involved in the North American medical cannabis market. How does this compare to Europe?

  • 17:10 - 17:20 | Going Public

    IPO's are happening in Canada. Will the trend move to Europe?

  • 17:20 - 17:30 | Preventing Exploitation

    In markets where medical cannabis is legal and recreational cannabis is not, what measures are in place to stop exploitation?

  • 17:30 - 17:40 | Commercialisation

    Since medical cannabis isn't legal everywhere, advertising on social media and other digital platforms is limited. How might this effect an investor's decision on financing start-ups?

  • 17:40 - 17:50 | Traditional Financing Models

    How is stigma and uncertainty preventing medical cannabis companies from raising capital from banks and lending institutions and how can this be addressed?

  • 17:50 - 18:00 | Supply and Demand

    Cover supply is a problem affecting certain markets. How can a company accurately forecast demand?

  • 18:30 - 20:00 | Networking Drinks

  • 19:00 - 23:00 | VIP Networking Dinner

CONTACT

CANNABIZ SUMMIT WORLD, GAMING HUB,

JUDGE PAOLO DEBONO STR, MSIDA, MSD2032, MALTA

Viking PC Health Ltd. is a company registered in Malta, having company registration number C54356 and VAT number MT20561207. Copyright Viking PC Health Ltd. All rights reserved © 2011 – 2019.